Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
A Phase I Study of Pyrimethamine in Patients With GM-2 Gangliosidosis
This study has been suspended.
( Lack of sufficient funds )
Study NCT00679744 Information provided by FDA Office of Orphan Products Development
First Received: May 15, 2008 Last Updated: October 1, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
G(M2) Ganglioside
Tay-Sachs Disease Ganglioside
Sandhoff Disease Ganglioside
Additional conditions recognized in this trial
Gangliosidoses
Gangliosidoses, GM2
Sandhoff Disease
Tay-Sachs Disease
More general conditions related to this trial
Brain Diseases
Brain Diseases, Metabolic
Brain Diseases, Metabolic, Inborn
Central Nervous System Diseases
Genetic Diseases, Inborn
Lipid Metabolism Disorders
Lipid Metabolism, Inborn Errors
Lipidoses
Lysosomal Storage Diseases
Lysosomal Storage Diseases, Nervous System
Metabolic Diseases
Metabolism, Inborn Errors
Nervous System Diseases
Sphingolipidoses
Interventions listed in this trial
Pyrimethamine
More general drug interventions related to this trial
Anti-Infective Agents
Antimalarials
Antiparasitic Agents
Antiprotozoal Agents
Enzyme Inhibitors
Folic Acid Antagonists
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
ExSAR Corporation
University Hospitals of Cleveland
New York University School of Medicine
The Hospital for Sick Children
Back to top of Main Content
